Novel Extracorporeal Therapy for the Reversal of Septic Shock and Restoring Hemodynamic Stability

逆转感染性休克并恢复血流动力学稳定性的新型体外疗法

• 批准号: 10744682
• 负责人: Phillip Chan
• 金额: $ 0.65万
• 依托单位: CYTOSORBENTS, INC.
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-01 至 2023-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10744682
• 关键词: Administrative Supplement; Businesses; Caring; Cessation of life; Consultations; Counseling; Coupled; Endotoxins; Excision; Fees; Formulation; Funding; Immune response; Infection; Intellectual Property; Laws; Legal; Legal patent; Marketing; Mediating; Organ failure; Plasma; Polymer Chemistry; Polymers; Reaction; Sepsis; Septic Shock; Time; cytokine; effective therapy; gram-negative sepsis; hemodynamics; innovation; novel; novel therapeutics; pathogen; septic; sound

PROJECT SUMMARY The funds from this administrative supplement will be utilized for Technical and Business Assistance (TABA). Specifically, we intend to use the funds to cover intellectual property strategy consultation fees to provide us with a sound patent strategy for our novel polymer sorbent LPSorb. Sepsis is an extreme reaction to pathogen infection and is one of the deadliest conditions in the world. The field of sepsis care currently lacks an effective treatment to counteract both the bacterial-derived endotoxins found in certain types of sepsis and the massive cytokine-mediated immune response to the infection that can lead to organ failure and death. LPSorb has demonstrated the potential to be an extremely effective extracorporeal endotoxin adsorber. When coupled with our cytokine adsorber CytoSorb, which is currently on the market, LPSorb should provide a novel and effective therapy for deadly Gram-negative sepsis. The innovative formulation developed by our polymer chemistry team will require intellectual property protection to allow for continued innovation and to provide maximum revenue, enabling the establishment of a viable new product line for the company. To achieve this, we propose to use these supplemental funds to engage our longtime IP counsel BakerHostetler to seek intellectual property counsel to develop a suitable patent strategy which will ultimately enable us to efficiently pursue both material and application patents for this innovative product.

项目摘要 这笔行政补贴的资金将用于技术和业务 援助（TABA）。具体而言，我们打算将资金用于知识产权 战略咨询费，为我们的新型聚合物提供合理的专利战略 吸附剂LPSorb. 败血症是对病原体感染的一种极端反应，也是世界上最致命的疾病之一 世界脓毒症护理领域目前缺乏有效的治疗方法来抵消脓毒症的治疗。 在某些类型的脓毒症中发现的细菌源性内毒素和大量的精氨酸介导的 对感染的免疫反应，可能导致器官衰竭和死亡。 LPSorb已被证明是一种非常有效的体外内毒素 吸附器当与我们目前上市的细胞因子吸附剂CytoSorb结合使用时， LPSorb应为致命的革兰氏阴性脓毒症提供一种新的有效治疗方法。 由我们的聚合物化学团队开发的创新配方将需要知识分子 财产保护，以允许持续创新，并提供最大的收入， 为公司建立可行的新产品线。 为了实现这一目标，我们建议使用这些补充资金， 向BakerHostetler寻求知识产权律师，以开发合适的专利 这些战略最终将使我们能够有效地追求材料和应用 这一创新产品的专利。